(Q34658247)

3 August 2017

title

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study (English)

1 reference

3 August 2017

1 reference

E Van Cutsem

1

1 reference

3 August 2017

C-P Li

2

1 reference

3 August 2017

E Nowara

3

1 reference

3 August 2017

G Aprile

4

1 reference

3 August 2017

M Moore

5

1 reference

3 August 2017

I Federowicz

6

1 reference

3 August 2017

J-L Van Laethem

7

1 reference

3 August 2017

C Hsu

8

1 reference

3 August 2017

C K Tham

9

1 reference

3 August 2017

S M Stemmer

10

1 reference

3 August 2017

R Lipp

11

1 reference

3 August 2017

A Zeaiter

12

1 reference

3 August 2017

A Fittipaldo

13

1 reference

3 August 2017

Z Csutor

14

1 reference

3 August 2017

B Klughammer

15

1 reference

3 August 2017

X Meng

16

1 reference

3 August 2017

T Ciuleanu

17

1 reference

3 August 2017

language of work or name

English

0 references

publication date

23 September 2014

1 reference

British Journal of Cancer

3 August 2017

published in

1 reference

3 August 2017

volume

111

1 reference

3 August 2017

issue

11

1 reference

3 August 2017

page(s)

2067-2075

1 reference

The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

Erlotinib in previously treated non-small-cell lung cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4260026

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.494

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.494

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.494

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.494

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.494

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.494

Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25247318

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25247318

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2014.494

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference